Northwest Biotherapeutics (NWBO) 5.88 $NWBO
NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY
PR Newswire - Tue Apr 15, 12:11PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.
Northwest Biotherapeutics expects USD32m in financing
M2 - Fri Apr 11, 7:05AM CDT
US-based biotechnology company Northwest Biotherapeutics (NWBO) said on Thursday that it has signed a registered direct placement of up to USD32m with a single institutional investor.
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.
at The Street - Thu Apr 10, 9:24AM CDT
An explanation of Northwest Bio's "up to" $32 million financing deal.
NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION
PR Newswire - Thu Apr 10, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 9, 2014, it entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million. The Stock Purchase Agreement provides for the sale of an initial $15 million of common stock at $6.60 per share (approximately 8% discount to the closing market price). The Stock Purchase Agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (approximately 5% premium to the closing market price) during the twelve months following the initial closing. There are no warrants in the financing.
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
PR Newswire - Mon Apr 07, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study
at The Street - Thu Apr 03, 7:30AM CDT
Northwest Bio is now acknowledging that no agreement with FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Bio, DCVax and 'Compassionate Use'
at The Street - Sat Mar 29, 10:33AM CDT
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
PR Newswire - Fri Mar 28, 12:03PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs.
Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum
PR Newswire - Fri Mar 28, 10:00AM CDT
The US markets saw a negative sentiment on Thursday, March 27, 2014, with the NASDAQ Composite closing at 4,151.23, down 0.54%, the Dow Jones Industrial Average ending the session at 16,264.23, down 0.03% and the S&P 500 edging 0.19% lower to finish the trading session at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors ended in negative, while some positive momentum were observed in the Telecommunication Services, Energy, and Utilities sectors. A number of stocks saw large movements, including Signet Jewelers Ltd (NYSE: SIG), Quicksilver Resources Inc. (NYSE: KWK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Goodrich Petroleum Corp. (NYSE: GDP). Free technical research on SIG, KWK, NWBO and GDP can be downloaded upon signing up at:
Why Northwest Biotherapeutics, Orthofix International, and Conn's Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 4:15PM CDT
Despite today's economic data being mixed, it predominantly leaned toward being better than expected. Yet, the broad-based S&P 500 still pushed lower on the day. Perhaps no piece of economic data stood out more than the final estimate of...
Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study
at The Street - Thu Mar 27, 3:21PM CDT
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a...
Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
PR Newswire - Thu Mar 27, 7:15AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an overview of the Company's DCVax® cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NW Bio Refutes False Claims By Adam Feuerstein
PR Newswire Europe - Wed Mar 12, 10:23PM CDT
Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today refuted what the Company strongly believes are false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11.
NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY
PR Newswire - Tue Apr 15, 12:11PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.
Northwest Biotherapeutics expects USD32m in financing
M2 - Fri Apr 11, 7:05AM CDT
US-based biotechnology company Northwest Biotherapeutics (NWBO) said on Thursday that it has signed a registered direct placement of up to USD32m with a single institutional investor.
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.
at The Street - Thu Apr 10, 9:24AM CDT
An explanation of Northwest Bio's "up to" $32 million financing deal.
NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION
PR Newswire - Thu Apr 10, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on April 9, 2014, it entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million. The Stock Purchase Agreement provides for the sale of an initial $15 million of common stock at $6.60 per share (approximately 8% discount to the closing market price). The Stock Purchase Agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (approximately 5% premium to the closing market price) during the twelve months following the initial closing. There are no warrants in the financing.
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
PR Newswire - Mon Apr 07, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading.
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries
at The Street - Fri Apr 04, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study
at The Street - Thu Apr 03, 7:30AM CDT
Northwest Bio is now acknowledging that no agreement with FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Northwest Bio, DCVax and 'Compassionate Use'
at The Street - Sat Mar 29, 10:33AM CDT
Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
PR Newswire - Fri Mar 28, 12:03PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false and misleading claims by Adam Feuerstein in an article posted Thursday, March 27, after NW Bio's public presentation of significant positive news about all of the Company's programs.
Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum
PR Newswire - Fri Mar 28, 10:00AM CDT
The US markets saw a negative sentiment on Thursday, March 27, 2014, with the NASDAQ Composite closing at 4,151.23, down 0.54%, the Dow Jones Industrial Average ending the session at 16,264.23, down 0.03% and the S&P 500 edging 0.19% lower to finish the trading session at 1,849.04. The losses were broad based as seven out of ten sectors ended the session in negative. During the session, Information Technology, Financials, and Consumer Discretionary sectors ended in negative, while some positive momentum were observed in the Telecommunication Services, Energy, and Utilities sectors. A number of stocks saw large movements, including Signet Jewelers Ltd (NYSE: SIG), Quicksilver Resources Inc. (NYSE: KWK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Goodrich Petroleum Corp. (NYSE: GDP). Free technical research on SIG, KWK, NWBO and GDP can be downloaded upon signing up at:
Why Northwest Biotherapeutics, Orthofix International, and Conn's Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 4:15PM CDT
Despite today's economic data being mixed, it predominantly leaned toward being better than expected. Yet, the broad-based S&P 500 still pushed lower on the day. Perhaps no piece of economic data stood out more than the final estimate of...
Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study
at The Street - Thu Mar 27, 3:21PM CDT
Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a...
Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
PR Newswire - Thu Mar 27, 7:15AM CDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an overview of the Company's DCVax® cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct. This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NW Bio Refutes False Claims By Adam Feuerstein
PR Newswire Europe - Wed Mar 12, 10:23PM CDT
Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today refuted what the Company strongly believes are false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11.
